AbbVie vs Denali Therapeutics
Free cash flow was $17.8 billion at AbbVie and −$422 million at Denali Therapeutics.
Side by side
| AbbVie | Denali Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $61.2B | $0M |
| Revenue growth | 8.6% | — |
| Revenue growth a year, last 5 years | 6.0% | — |
| Gross margin | 70.2% | — |
| Operating margin | 24.6% | — |
| Net margin | 6.9% | — |
| Free cash flow | $17.8B | −$422M |
| Free cash flow margin | 29.1% | — |
| Return on capital | 15.7% | — |
| Net debt to EBITDA | 2.7x | — |
| Dividends and buybacks | $12.6B | $0M |
| Change in diluted share count | 0.0% | 5.0% |
| Last close | $295.03 | $18.74 |
| P/E at the last close | 50.8× | — |
| Insider trades, last 12 months | sold $30.8 million | sold $1.3 million |
| Piotroski F-score | 7 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
AbbVieDenali Therapeutics
Operating margin
Percent of revenue
AbbVieDenali Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AbbVieDenali Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the AbbVie and Denali Therapeutics pages.